PharmaDrug Inc CEO Daniel Cohen tells Proactive that its enteric-coated oral formulation of cepharanthine (PD-001), when combined with cabazitaxel, significantly reduces tumor volume, and provides improved prostate cancer tumor growth inhibition.- As a result, the Toronto, Ontario-based specialty pharma company has filed a second provisional patent application to support new claims specifically related to the in vivo dosing of cepharanthine in combination with taxane-family members for the treatment of prostate cancer.
PharmaDrug files patent after positive findings for PD-001 and chemotherapy in prostate cancer study
